The neuropharmacological effects of electroconvulsive shock and their relationship to the therapeutic effect of electroconvulsive therapy in depression.
D000768:Anesthesia, General; D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use; D001058:Apomorphine; D001522:Behavior, Animal / Q000502:physiology; D001921:Brain / Q000502:physiology; D003345:Corticosterone / Q000502:physiology; D003863:Depression / Q000628:therapy*; D004298:Dopamine / Q000502:physiology; D004565:Electroconvulsive Therapy; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D051379:Mice; D009043:Motor Activity / Q000502:physiology; D009638:Norepinephrine / Q000502:physiology; D051381:Rats; D012640:Seizures / Q000139:chemically induced; D012701:Serotonin / Q000502:physiology; D005680:gamma-Aminobutyric Acid / Q000502:physiology
D000928:Antidepressive Agents; D012701:Serotonin; D005680:gamma-Aminobutyric Acid; D013006:Growth Hormone; D001058:Apomorphine; D004298:Dopamine; D003345:Corticosterone; D009638:Norepinephrine